BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Purchased by Cwm LLC

Cwm LLC raised its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 132.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,442 shares of the company’s stock after purchasing an additional 1,964 shares during the period. Cwm LLC’s holdings in BridgeBio Pharma were worth $88,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BBIO. Bfsg LLC raised its holdings in BridgeBio Pharma by 175.6% in the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after buying an additional 790 shares during the period. Headlands Technologies LLC purchased a new position in BridgeBio Pharma in the second quarter valued at approximately $48,000. EntryPoint Capital LLC purchased a new position in BridgeBio Pharma in the first quarter valued at approximately $117,000. Amalgamated Bank raised its holdings in BridgeBio Pharma by 24.7% in the second quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock valued at $123,000 after buying an additional 962 shares during the period. Finally, Quarry LP raised its holdings in BridgeBio Pharma by 27.1% in the second quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $190,000 after buying an additional 1,600 shares during the period. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Pharma Price Performance

BridgeBio Pharma stock opened at $23.84 on Friday. The company has a market cap of $4.46 billion, a PE ratio of -7.40 and a beta of 1.08. The company has a fifty day moving average price of $26.10 and a two-hundred day moving average price of $26.48. BridgeBio Pharma, Inc. has a 12 month low of $21.62 and a 12 month high of $44.32.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.61. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $3.96 million. During the same period last year, the firm posted ($0.98) EPS. The business’s revenue was up 32.1% compared to the same quarter last year. Equities research analysts anticipate that BridgeBio Pharma, Inc. will post -2.56 earnings per share for the current year.

Insider Buying and Selling

In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the sale, the insider now owns 25,260,971 shares in the company, valued at approximately $650,470,003.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the completion of the sale, the insider now owns 25,260,971 shares of the company’s stock, valued at approximately $650,470,003.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $676,234.41. Following the sale, the chief executive officer now directly owns 4,897,443 shares of the company’s stock, valued at $120,917,867.67. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,831,544 shares of company stock valued at $150,128,821 over the last 90 days. 24.66% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have issued reports on BBIO shares. Oppenheimer started coverage on shares of BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a “market perform” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $43.00 price objective on shares of BridgeBio Pharma in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $70.00 price objective on shares of BridgeBio Pharma in a research report on Monday, September 16th. Leerink Partners lowered their price objective on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Finally, Scotiabank started coverage on shares of BridgeBio Pharma in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $44.00 price objective for the company. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.50.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.